| Investments in and Advances to Affiliates, Schedule of Investments [Text Block] |
NOTE 10. INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS
Under the 1940 Act, the Company is required to identify investments where it owns greater than 5% (but less than 25%) of the portfolio company’s outstanding voting shares as an affiliate of the Company. Also, under the 1940 Act, the Company is required to identify investments where it owns greater than 25% of the portfolio company’s outstanding voting shares as a controlled investment of the Company. A summary of the Company’s investments in affiliates and controlled investments for the period from December 31, 2025, through March 31, 2026, is noted below:
| AFFILIATE/CONTROLLED INVESTMENTS* | | VALUE AT
12/31/25 | | | PURCHASE/
MERGER | | | INTEREST | | | SALES/
MATURITY/
EXPIRATION | | | REALIZED
GAIN (LOSS) | | | CHANGE IN APPRECIATION/
DEPRECIATION | | | VALUE
3/31/26 | | | SHARES HELD AT
3/31/26 | |
| Medical Devices | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| IntraOp Medical Corp. Convertible Note* | | | 600 | | | | — | | | | — | | | | — | | | | — | | | | (303 | ) | | | 297 | | | | 10,961,129 | |
| IntraOp Medical Corp. Convertible Note* | | | 71 | | | | — | | | | — | | | | — | | | | — | | | | (36 | ) | | | 35 | | | | 1,300,000 | |
| IntraOp Medical Corp. Convertible Note* | | | 28 | | | | — | | | | — | | | | — | | | | — | | | | (15 | ) | | | 13 | | | | 500,000 | |
| IntraOp Medical Corp. Convertible Note* | | | 28 | | | | — | | | | — | | | | — | | | | — | | | | (15 | ) | | | 14 | | | | 500,000 | |
| IntraOp Medical Corp. Convertible Note* | | | 41 | | | | — | | | | — | | | | — | | | | — | | | | (21 | ) | | | 20 | | | | 750,000 | |
| IntraOp Medical Corp. Convertible Note* | | | 28 | | | | — | | | | — | | | | — | | | | — | | | | (13 | ) | | | 14 | | | | 500,000 | |
| IntraOp Medical Corp. Convertible Note* | | | 55 | | | | — | | | | — | | | | — | | | | — | | | | (28 | ) | | | 27 | | | | 1,000,000 | |
| IntraOp Medical Corp. Convertible Note* | | | 28 | | | | — | | | | — | | | | — | | | | — | | | | (15 | ) | | | 13 | | | | 500,000 | |
| IntraOp Medical Corp. Convertible Note* | | | 22 | | | | — | | | | — | | | | — | | | | — | | | | (11 | ) | | | 11 | | | | 400,000 | |
| IntraOp Medical Corp. Term Note* | | | 164 | | | | — | | | | — | | | | — | | | | — | | | | (83 | ) | | | 81 | | | | 3,000,000 | |
| IntraOp Medical Corp. Convertible Note* | | | 27 | | | | — | | | | — | | | | — | | | | — | | | | (13 | ) | | | 14 | | | | 500,000 | |
| IntraOp Medical Corp. Convertible Note* | | | 55 | | | | — | | | | — | | | | — | | | | — | | | | (28 | ) | | | 27 | | | | 1,000,000 | |
| IntraOp Medical Corp. Convertible Note* | | | 27 | | | | — | | | | — | | | | — | | | | — | | | | (13 | ) | | | 14 | | | | 500,000 | |
| IntraOp Medical Corp. Convertible Note* | | | 27 | | | | — | | | | — | | | | — | | | | — | | | | (13 | ) | | | 14 | | | | 500,000 | |
| IntraOp Medical Corp. Convertible Note* | | | 55 | | | | — | | | | — | | | | — | | | | — | | | | (28 | ) | | | 27 | | | | 1,000,000 | |
| IntraOp Medical Corp. Convertible Note* | | | 27 | | | | — | | | | — | | | | — | | | | — | | | | (13 | ) | | | 14 | | | | 500,000 | |
| IntraOp Medical Corp. Convertible Note* | | | 27 | | | | — | | | | — | | | | — | | | | — | | | | (13 | ) | | | 14 | | | | 500,000 | |
| IntraOp Medical Corp. Convertible Note* | | | 27 | | | | — | | | | — | | | | — | | | | — | | | | (13 | ) | | | 14 | | | | 500,000 | |
| IntraOp Medical Corp. Convertible Note* | | | 11 | | | | — | | | | — | | | | — | | | | — | | | | (6 | ) | | | 5 | | | | 200,000 | |
| IntraOp Medical Corp. Convertible Note* | | | 38 | | | | — | | | | — | | | | — | | | | — | | | | (19 | ) | | | 19 | | | | 700,000 | |
| IntraOp Medical Corp. Convertible Note* | | | 8 | | | | — | | | | — | | | | — | | | | — | | | | (4 | ) | | | 4 | | | | 150,000 | |
| IntraOp Medical Corp. Convertible Note* | | | 19 | | | | — | | | | — | | | | — | | | | — | | | | (10 | ) | | | 9 | | | | 350,000 | |
| IntraOp Medical Corp. Preferred Stock* | | | 0 | | | | — | | | | — | | | | — | | | | — | | | | — | | | | 0 | | | | 26,856,187 | |
| IntraOp Medical Corp. Term Note* | | | 110 | | | | — | | | | — | | | | — | | | | — | | | | (56 | ) | | | 54 | | | | 2,000,000 | |
| Total Medical Devices | | $ | 1,523 | | | | — | | | $ | — | | | | — | | | | — | | | $ | (769 | ) | | $ | 754 | | | | | |
| Semiconductor Equipment | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Revasum, Inc. CDIs*(1) | | | 0 | | | | — | | | | — | | | | — | | | | — | | | | — | | | | 0 | | | | 39,774,889 | |
| Total Semiconductor Equipment | | $ | 0 | | | | — | | | $ | — | | | | — | | | | — | | | $ | — | | | $ | 0 | | | | | |
| Advanced Materials | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| UCT Coatings, Inc. Common Stock | | | 167,642 | | | | — | | | | — | | | | — | | | | — | | | | (24,082 | ) | | | 143,560 | | | | 1,500,000 | |
| Total Advanced Materials | | $ | 167,642 | | | | — | | | $ | — | | | | — | | | | — | | | $ | (24,082 | ) | | $ | 143,560 | | | | | |
| Automotive | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Wrightspeed, Inc. Common Stock* | | | 0 | | | | — | | | | — | | | | — | | | | — | | | | — | | | | 0 | | | | 69,102 | |
| Wrightspeed, Inc. Preferred Stock* | | | 0 | | | | — | | | | — | | | | — | | | | — | | | | — | | | | 0 | | | | 60,733,693 | |
| Total Automotive | | $ | 0 | | | | — | | | $ | — | | | | — | | | | — | | | $ | — | | | $ | 0 | | | | | |
| Total Affiliates and Controlled Investments | | $ | 169,165 | | | | — | | | $ | — | | | | — | | | $ | — | | | $ | (24,851 | ) | | $ | 144,314 | | | | | |
| Total Affiliates | | | 167,642 | | | | — | | | | — | | | | — | | | | — | | | | (24,082 | ) | | | 143,560 | | | | | |
| Total Controlled Investments | | $ | 1,523 | | | | — | | | $ | — | | | | — | | | $ | — | | | $ | (769 | ) | | $ | 754 | | | | | |
| * | Controlled Investments. |
| (1) | CDI CHESS Depositary Interests |
| | |
As of March 31, 2026, Kevin Landis, the Company’s Chairman, President and Chief Executive Officer, represented the Company and sat on the boards of directors of IntraOp Medical Corp.; Revasum, Inc.; and Wrightspeed, Inc. As of March 31, 2026, Mr. Landis served as interim CEO at IntraOp Medical Corp. and Wrightspeed, Inc. Serving as a director or officer of portfolio companies may cause conflicts of interest. The Advisor has adopted various procedures to ensure that the Company will not be unfavorably affected by these potential conflicts.
|